Tolerability, pharmacokinetics, and pharmacodynamics of JNJ 39588146 in volunteers and patients with heart failure.

Trial Profile

Tolerability, pharmacokinetics, and pharmacodynamics of JNJ 39588146 in volunteers and patients with heart failure.

Completed
Phase of Trial: Phase I

Latest Information Update: 09 Sep 2012

At a glance

  • Drugs JNJ 39588146 (Primary)
  • Indications Heart failure
  • Focus Adverse reactions; Pharmacodynamics; Pharmacokinetics
  • Sponsors Janssen Research & Development
  • Most Recent Events

    • 09 Sep 2012 New trial record
    • 29 Aug 2012 Results from part 3 of the study presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
    • 29 Aug 2012 Results from part 2 of the study were presented at the ESC Congress 2012: Annual Congress of the European Society of Cardiology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top